Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

The study population for this Phase 2 study will include men and women ≥ 18 with confirmed renal cell carcinoma who have progressed on adjuvant anti-PD-1/PD-L1 therapy, the current standard of care. Subjects will be randomized to Arm A or Arm B. Study treatment will be given in 28-day (4 week) cycles. Arm A treatment will consist of zanzalintinib (XL092) alone and will be taken once daily continuously (Day 1-Day 28). Arm B treatment will consist of XL092 plus nivolumab. XL092 will be taken once daily continuously (Day 1-Day 28) and nivolumab will be administered every 4 weeks (Day 1). Treatmen

Trial Details

NCT ID
NCT06863311
Phase
PHASE2
Sponsor
Karie Runcie
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • XL092
  • Nivolumab
Locations (sample)
  • La Jolla, California, United States|32.84727,-117.2742
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • St Louis, Missouri, United States|38.62727,-90.19789
  • New York, New York, United States|40.71427,-74.00597
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be…
  • Age ≥ 18 years at the time of consent.
  • ECOG Performance Status of 0-1 within 28 days prior to registration.
  • Advanced or metastatic RCC with a clear cell component.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →